Cohance Lifesciences Ltd Q2FY26: The ₹23,547 Cr CDMO Circus That’s Equal Parts Science, Drama, and Soap Opera

1. At a Glance

Once upon a time in Hyderabad, a bunch of chemists decided to play God — but with molecules. Thus was born Cohance Lifesciences Ltd, a Contract Development and Manufacturing Organization (CDMO) with global ambitions and a flair for corporate theatrics.

With a market cap of ₹23,547 crore, a stock price of ₹616, and a P/E ratio of 68.6, the company trades like it’s the next Divi’s Labs, even though its quarterly profits just halved. Q2FY26 numbers screamed turbulence: Revenue ₹556 crore (down 8% QoQ) and PAT ₹74 crore (down 46.5%). But with EBITDA margins still hovering near 22%, Cohance proves that even when it’s bleeding, it bleeds premium margins.

Its ROE stands at 12.7%, ROCE at 14.9%, and debt levels are modest at ₹451 crore (Debt/Equity 0.12). Yet, the market gave it a solid thappad — the stock is down 52% in one year. And just when investors were digesting that, came the USFDA inspection drama, MD resignations, promoter stake sales, and a merger with itself (yes, really).

If the Bible says, “Blessed are the pure in heart,” then Cohance’s balance sheet needs cleansing rituals — not because it’s dirty, but because it’s complicated enough to give auditors existential dread.

2. Introduction

Cohance Lifesciences is Hyderabad’s answer to the global CDMO boom — the fine-chemical, high-margin world where chemists in lab coats do custom manufacturing for Big Pharma. Imagine if Divi’s Labs and Dr. Reddy’s had a hyperactive child who refused to sit still — that’s Cohance.

From synthesizing New Chemical Entities (NCEs) to scaling late-stage molecules for clinical and commercial use, Cohance wants to be the go-to lab for every global innovator’s manufacturing problem.

But behind the glossy investor decks lies a company juggling too many test tubes at once. It’s managing mergers, acquisitions, resignations, and USFDA visits — all while trying to “double its business in 5 years.”

Half of its revenue still depends on the Pharma CDMO segment (72%), while Specialty Chemicals has gone from being the star child to the neglected step-sibling (a 76% YoY drop in H1FY25). Formulations, however, are the new rising star, growing 28% YoY.

Cohance’s story is a wild mix of chemistry, capital, and chaos. Welcome to the only pharma company where M&A announcements and regulatory warnings come out in the same week.

3. Business Model – WTF Do They Even Do?

If you thought CDMO means “Confusing Data, Mysterious Operations,” you’re not far off. Cohance’s business model has three broad arms — all busy reacting, extracting, and distracting investors with jargon.

1. Pharma CDMO (72% of revenue):
   The breadwinner. Cohance helps pharma innovators develop and manufacture complex intermediates and APIs. They handle everything from process R&D to Phase-3 clinical support and commercial-scale production.
   They’ve already commercialized 12 patented molecules and are developing 7 more in Phase-3. That’s serious science. The catch? FY25 H1 revenue here fell 4% YoY because clients delayed shipments.
2. Specialty Chemicals (6% of revenue):
   Once a booming line, now the problem child. Products include Carprofen, Calcium Acetate, Gabapentin, Iso Sulfan Blue, and Rifapentine — the kind of names that make even chemistry professors yawn.
   A 76% YoY revenue fall in H1FY25 turned this division from profit center to patience test. Management calls it a “strategic business unit.” Investors call it “why the hell are margins falling.”
3. Formulations & Others (22% of revenue):
   The new hope — formulations, analytical development, injectables, and even complex biologics. This vertical grew 28% YoY in H1FY25 and is poised to lead recovery.

With 3 manufacturing facilities and 2 R&D centers across Telangana and Andhra Pradesh totaling 1,800+ KL reactor capacity, Cohance has the hardware to match its ambitions. They even invested ₹69 crore in H1FY25 to expand capacity and set up a new R&D hub at Genome Valley, Hyderabad.

So, yes, they’re building a science empire — one molecule, one merger, and one USFDA inspection at a time.

4. Financials Overview

Annualized EPS = ₹1.94 × 4 = ₹7.76
At CMP ₹616 → P/E ~79x

The numbers scream “premium business, patience required.” A dip in shipments hit revenue, while higher depreciation (new assets, new M&A) chewed profits.

The gross margin (74%) is world-class, but the EBITDA margin dropped to 22%, showing the integration costs of Sapala Organics and NJ Bio acquisitions are still biting.

5. Valuation Discussion – Fair Value Range

Let’s decode the madness with three quick yardsticks:

• EPS (TTM): ₹11.2
• Industry P/E: 32
• Current P/E: 68.6

If Cohance were valued more sanely like Divi’s (≈70x in its best years) or Torrent (≈60x), we’d get:

Fair Value = ₹11.2 × (40–60) = ₹448 – ₹672 per share.

Now let’s peek at EV/EBITDA:

• EV = ₹23,900 Cr
• EBITDA (TTM) = ₹580 Cr
  → EV/EBITDA = 41x

Divi’s trades near 30x, so Cohance is definitely at a premium it hasn’t earned yet.

✅ Educational Fair Value Range: ₹450 – ₹650 per share.
📜 Disclaimer: This fair value range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

Cohance’s press releases could rival Netflix thrillers.

• USFDA Woes (Sept 2025): Nacharam FDF Unit-I got slapped with six Form 483 observations and classified as “Official Action Indicated (OAI).” Thankfully, the site contributes <2% of FY25 revenue — small mercy.
• MD Exit (Oct 2025): Dr. V. Prasada Raju resigned. CFO Himanshu Agarwal immediately took over as Whole-time Director. Investors responded with a collective “uh oh.”
• Promoter Sell-off (Sept 2025): Jusmiral Holdings sold 8.93% stake for ₹52.82 Cr, reducing holding to 24.15%. Proceeds reportedly went to repay notes.
• Acquisitions Mania:
  • Acquired NJ Bio Inc (56% stake) for $64.4 Mn, expanding into ADC (Antibody Drug Conjugates) manufacturing.
  • Bought Sapala Organics (67.5% stake) for ₹229 Cr, entering the oligonucleotide drug space.
• Capex Bonanza: ₹230 Mn into a cGMP oligonucleotide facility with 700 kg annual capacity and $10 Mn expansion at NJ Bio for ADC bioconjugation.

If Cohance were a Bollywood film, this quarter would be titled “Merger, M&A aur FDA.”

7. Balance Sheet

Three words: balance sheet explosion.
Total assets doubled in six months — a mix of acquisitions (NJ Bio, Sapala), R&D buildouts, and merger integration. Borrowings are rising but still manageable at 0.12 D/E.

🔹 Commentary:

• Cohance is clearly in expansion overdrive.
• Liabilities ballooned due to deferred payments and consolidation of acquired entities.
• Fixed assets jumped to ₹3,116 Cr — that’s serious steel and stainless steel reactors.

8. Cash Flow – Sab Number Game Hai

They’re generating positive cash flows — barely. Most operating inflow is being swallowed by investment outflows. That’s fine if growth pays off, but right now, free cash flow yield is miserable (CMP/FCF = 116x — yikes).

It’s like a lab that’s making great molecules but hasn’t figured out how to bill clients on time.

9. Ratios – Sexy or Stressy?

Margins and returns are clearly under pressure, but not in free fall. Cohance is in the “integration phase,” i.e., the polite way to say “give us a year before we stop burning cash.”

10. P&L Breakdown – Show Me the Money

After peaking in FY22, revenue slumped, courtesy of global pharma destocking and delayed client orders. But FY26 TTM revenue (₹2,252 Cr) shows a strong recovery trajectory.

The EBITDA margin compression from 44% → 26% is the cost of “becoming global.” Turns out, buying NJ Bio and Sapala doesn’t just cost money; it costs sleep.

11. Peer Comparison

At one-tenth of Divi’s revenue but nearly the same P/E, Cohance’s valuation looks like it’s based more on Advent’s pedigree than earnings.

Divi’s makes chemistry look divine. Cohance is still figuring out whether it’s a lab or a leveraged conglomerate.

12. Miscellaneous – Shareholding and Promoters

Promoter group drama could fill a soap opera:

• Berhyanda Ltd (Advent International) owns ~33%.
• Jusmiral Holdings dropped to 24.15% after dumping shares in Sept 2025.
• Mutual fund heavyweights like DSP, UTI, SBI Life, and Tata AIA are on board.

But the biggest red flag? 100% promoter shares are pledged. Even a pharma intern knows that’s riskier than mixing sodium with water.

13. Corporate Governance – Angels or Devils?

CRISIL recently upgraded Cohance to AA-/Positive, reaffirming its A1+ short-term rating. So, financially clean. But governance has been… dramatic.

In one year, they:

• Changed CEO, MD, and CFO positions.
• Saw promoters sell stakes to repay debt.
• Had one facility slapped with USFDA OAI.
• Reallocated ₹548 crore post-acquisition to NJ Bio and Sapala.

The company insists all CAPAs are filed and facilities are “compliant.” Translation: we’re fine, just don’t ask too many questions.

14. Industry Roast and Macro Context

The CDMO sector is India’s latest export flex — a cocktail of chemistry, compliance, and capital. As Big Pharma outsources more R&D and API manufacturing, India’s scientists are doing what IT did 20 years ago: selling brainpower globally.

But here’s the twist: every pharma player now wants to be a CDMO. Divi’s, Syngene, Laurus, Aragen, Suven, and now Cohance — all claiming to be the chosen one for “innovation manufacturing.”

The problem? Everyone’s margins are under attack. Clients squeeze, regulators poke, and USFDA flies in uninvited.

Cohance, with its acquisitions and new R&D facilities, wants to become India’s answer to Lonza. But right now, it’s behaving more like a chemistry experiment mid-reaction — looks exciting but could go boom.

15. EduInvesting Verdict

Cohance Lifesciences is what happens when global ambition meets domestic volatility.

In pure numbers:

• Revenue: ₹1,051 Cr → ₹2,252 Cr (in 2 years)
• PAT: ₹300 Cr → ₹343 Cr (modest growth, margin hit)
• Debt: ₹65 Cr → ₹451 Cr (rising but still healthy)
• ROE: 21% → 12.7% (ouch)

Strengths:

• Backed by Advent International, one of the world’s top private equity firms.
• Strong CDMO order book and diversified R&D assets.
• Expanding into futuristic fields like ADCs and oligonucleotides.
• Solid margins despite turbulence.

Weaknesses:

• Promoter pledging = danger siren.
• USFDA issues = recurring migraine.
• High valuation = low room for error.
• Overdependence on acquisitions for growth.

Opportunities:

• Rising global outsourcing in pharma manufacturing.
• Capacity expansion across Genome Valley and NJ Bio.
• New CEO-CFO combo may bring operational discipline.

Threats:

• Tariff, compliance, and pricing pressure from global majors.
• M&A integration risks.
• Investor confidence dented after promoter sell-offs.

SWOT Summary:

So, will Cohance become the next Divi’s Labs? Not yet. Right now, it’s more like Divi’s Lab intern trying to handle six mergers, two FDA letters, and one angry shareholder at once.

The science is promising, the ambition is huge, but the execution needs some serious Cohance (pun intended).

Written by EduInvesting Team | November 17, 2025

SEO Tags: Cohance Lifesciences, CDMO India, Advent International, NJ Bio Acquisition, Sapala Organics, Pharma M&A, USFDA OAI, Hyderabad Genome Valley, Cohance Q2FY26 Results, EduInvesting Premium Analysis